The effects of suvorexant on sleep disorder and clinical findings of hemodialysis patients

The effects of suvorexant on sleep disorder and clinical findings of hemodialysis patients - The effects of suvorexant on sleep disorder and clinical findings of hemodialysis patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023199

Enrollment

Registered

2016-07-16

Start date

2016-07-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia, maintenance hemodialysis patient

Interventions

The patients receive Suvorexant 20mg per day for 3 months. If the patients are elderly, they receive Suvorexant 15mg per day for 3 months. If the patients are already receiving other sleeping pills,

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients who receiving maintenance blood dialysis patients 2.Patients with insomnia 3.Patients who gave their written informed consent to participate for the present study 4.Age is 20 years old or more and gender is male or female

Exclusion criteria

Exclusion criteria: 1. Severe liver dysfunction 2. Severe respiratory dysfunction 3. Severe brain disorder 4. Patients having agents inhibiting CYP3A 5. Patients with severe dementia 6. Patients with no sleep wake rhythm due to bedridden state

Design outcomes

Primary

Measure	Time frame
Athens insomnia scale	—

Secondary

Measure	Time frame
1. Adverse effects 2. Self administered questionnaire about insomnia 3. Clinical findings (BMI, pre dialysis blood pressure, interdialytic weight gain, change of blood pressure during dialysis) and blood examinations	—

Countries

Japan

Contacts

Public ContactJun Ino

Toda Central General Hospital Department of Nephrology

pikkun46@hotmail.com048-442-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026